Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018226603) PROCESS FOR EXPLOITING SYNTHETIC LETHALITY BASED ON OVEREXPRESSION OF MYC ONCOGENE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/226603 International Application No.: PCT/US2018/035907
Publication Date: 13.12.2018 International Filing Date: 04.06.2018
IPC:
A61K 31/505 (2006.01) ,A61K 31/551 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
Applicants:
YANG, Dun [US/US]; US
Inventors:
YANG, Dun; US
ZHANG, Jing; GB
ZHANG, Shenqiu; GB
Agent:
SMEDLEY, James M; US
Priority Data:
15/996,69704.06.2018US
62/514,86104.06.2017US
Title (EN) PROCESS FOR EXPLOITING SYNTHETIC LETHALITY BASED ON OVEREXPRESSION OF MYC ONCOGENE
(FR) PROCÉDÉ D'EXPLOITATION DE LÉTALITÉ SYNTHÉTIQUE BASÉE SUR LA SUREXPRESSION D’ONCOGÈNE MYC
Abstract:
(EN) The present invention generally relates to inhibitor compounds and their use to selectively kill a class of cancer cells. Methods and means related to the treatment of cancers which overexpress the MYC family of oncogenes using Rho-associated protein kinase inhibitors, such as dimethylfasudil, which have shown to elicit cellular apoptosis, are provided herein.
(FR) La présente invention concerne de manière générale des composés inhibiteurs et leur utilisation pour tuer sélectivement une classe de cellules cancéreuses. L'invention concerne également des méthodes et des moyens associés au traitement de cancers qui surexpriment la famille MYC d'oncogènes, par l’utilisation des inhibiteurs de protéine kinase associés à Rho, tels que le diméthylfasudil, qui ont démontré qu'ils provoquent une apoptose cellulaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)